Managing Inflammation: Standard Care and Treatment
At a Glance
Cogan syndrome is treated urgently with corticosteroids to control inflammation in the eyes and inner ears. Doctors may add medicines that reduce steroid use or biologics for persistent disease, while early cochlear implant evaluation is important when hearing loss is permanent.
Treating Cogan syndrome requires a two-pronged approach: quickly stopping active inflammation to prevent permanent damage, and finding an individualized long-term plan that keeps the immune system in check without relying solely on steroids [1][2]. Because this condition is so rare, there is no single “standard” treatment protocol that works for everyone, and your doctors will likely adjust your medications based on how your eyes and ears respond [3].
Medication Safety Checklist
Because these medications suppress the immune system, a concrete safety plan is essential:
- Do Not Stop Steroids Abruptly: Rapidly tapering steroids on your own can cause dangerous adrenal suppression.
- Infection Precautions: Contact your team urgently if you develop a fever, shortness of breath, or unusual bruising [4].
- Routine Monitoring: When on steroids, monitor blood pressure and blood glucose, and discuss bone protection. Regular eye exams are needed to monitor for cataracts and glaucoma.
- Vaccines: Discuss vaccination planning before starting biologics or DMARDs.
- Pregnancy and Fertility: Discuss contraception and family planning before starting DMARDs like methotrexate or mycophenolate.
- Blood Tests: Ensure you know the specific blood-test schedule for each prescribed drug to monitor liver function and blood counts.
Treatment Timeline: Initial Attack
The first line of defense during a flare is usually corticosteroids (such as prednisone). These drugs work quickly to dampen the immune system’s attack on your eyes and inner ears [5].
- Systemic Steroids: High doses of oral or intravenous (IV) steroids are typically used to try to achieve rapid remission, though systemic therapy is tailored to your specific organ involvement [6]. In some cases, doctors may start with “pulse” IV steroids to address severe or sudden hearing loss [7].
- Topical Steroids: For eye-specific symptoms like keratitis, you may also be prescribed steroid eye drops or local injections to target the inflammation directly [6][8]. These require strict ophthalmologist supervision and should not be started before checking for infectious causes.
While steroids are highly effective for stopping a flare, they are not intended for long-term use. Prolonged use can lead to side effects such as increased eye pressure (ocular hypertension), bone thinning, and increased infection risk [9].
Long-Term Management: DMARDs
To reduce the need for steroids, doctors use DMARDs (disease-modifying antirheumatic drugs). These are “steroid-sparing” agents that help keep the disease in a state of remission [2].
- Common Options: Medications like methotrexate, azathioprine, and mycophenolate mofetil (MMF) are frequently used, often off-label [6][10]. These DMARDs are not interchangeable, and your doctor will select one based on your specific needs.
- The Goal: These drugs take longer to work than steroids (often weeks), but they allow your doctor to slowly “taper” or lower your steroid dose while still protecting your hearing and vision [7].
Biologic Therapies for Refractory Disease
If standard DMARDs do not sufficiently control your symptoms—especially if you have ongoing hearing loss—your team may recommend biologics. These are advanced medications that target specific proteins in the immune system.
Infliximab, a TNF-alpha inhibitor, is frequently used as an individualized option for refractory disease [11]. Small case reports and uncontrolled series have found that it may help improve or stabilize hearing in some patients who did not respond well to other treatments [11][2]. Other biologics, such as tocilizumab, are sometimes used off-label by specialists if your symptoms include inflammation of the large blood vessels [12][13]. It is important to understand that evidence for these drugs is based on small studies, and “stabilization” is not the same as the recovery of lost hearing. Irreversible hearing loss may not recover.
Surgical Options: Cochlear Implants
In some cases, despite the best medical efforts, the inner ear inflammation can lead to irreversible, profound hearing loss [14]. When this happens, a cochlear implant (CI) is a rehabilitation option [15].
A cochlear implant is an electronic device that bypasses the damaged parts of the inner ear to stimulate the hearing nerve directly. Timing is critical for this surgery because Cogan syndrome can cause cochlear ossification—the formation of new bone inside the delicate fluid-filled spaces of the inner ear [16][17].
- Early Intervention: If your doctors determine that hearing loss is permanent, early referral to a cochlear implant center is vital. If the ear becomes fully “ossified” (filled with bone), placing the implant becomes much more surgically complex [16][18].
- Outcomes: Some patients with Cogan syndrome see improvements in their ability to understand speech after receiving a cochlear implant, even if some ossification was present before surgery [14][19]. However, benefit and surgical feasibility vary widely depending on the degree of fibrosis, timing, active inflammation, and residual auditory-nerve function. An implant team determines candidacy and expected benefit.
Common questions in this guide
What treatment is usually started for a Cogan syndrome flare?
Why might I need a DMARD for Cogan syndrome?
When are biologic medicines such as infliximab considered for Cogan syndrome?
When should I ask about a cochlear implant for Cogan syndrome hearing loss?
What safety monitoring is needed while I take Cogan syndrome medicines?
Get notified when new evidence is published on Cogan syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Cogan's syndrome: State of the art of systemic immunosuppressive treatment in adult and pediatric patients.
Mora P, Calzetti G, Ghirardini S, et al.
Autoimmunity reviews 2017; (16(4)):385-390 doi:10.1016/j.autrev.2017.02.009.
PMID: 28232169 - 2
Cogan's syndrome: new therapeutic approaches in the biological era.
Padoan R, Cazzador D, Pendolino AL, et al.
Expert opinion on biological therapy 2019; (19(8)):781-788 doi:10.1080/14712598.2019.1611779.
PMID: 31056972 - 3
Unexpected Death in a Young Child With Cogan Syndrome.
Pastore S, Burlo F, Taddio A, et al.
Pediatrics 2026; (157(5)) doi:10.1542/peds.2025-073105.
PMID: 41980717 - 4
Cogan's syndrome with pyoderma gangrenosum: management of two uncommon disorders with aggressive presentation in a patient.
Chua EP, Mallett RB, Dahiya S
BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-223876.
PMID: 29925554 - 5
French protocol for diagnosis and management of Cogan's syndrome.
Arnaud L, Audemard-Verger A, Belot A, et al.
La Revue de medecine interne 2025; (46(2)):74-88 doi:10.1016/j.revmed.2024.09.007.
PMID: 39455380 - 6
Atypical Cogan's Syndrome Presenting as Anterior Scleritis: Case Report.
Mendes J, Mendes F, Valente Fortunato D, et al.
Case reports in ophthalmology 2026; (17(1)):371-379 doi:10.1159/000551227.
PMID: 42039758 - 7
Bilateral interstitial keratitis, erythema nodosum and atrial fibrillation as presenting signs of polyarteritis nodosa.
Vingopoulos F, Karagiotis T, Palioura S
American journal of ophthalmology case reports 2020; (18()):100619 doi:10.1016/j.ajoc.2020.100619.
PMID: 32140612 - 8
[Cogan syndrome – when several of our senses are affected].
Hedin E, Lyckberg H, Carlsson PI
Lakartidningen 2016; (113()).
PMID: 26928685 - 9
Lamotrigine-induced tubulointerstitial nephritis and uveitis-atypical Cogan syndrome.
Kolomeyer AM, Kodati S
European journal of ophthalmology 2015; (26(1)):e14-6.
PMID: 26350991 - 10
Atypical Cogan's syndrome: a case report and summary of current treatment options.
Jančatová D, Zeleník K, Komínek P, Matoušek P
International journal of pediatric otorhinolaryngology 2015; (79(3)):428-31.
PMID: 25600284 - 11
Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review.
Durtette C, Hachulla E, Resche-Rigon M, et al.
Autoimmunity reviews 2017; (16(12)):1219-1223 doi:10.1016/j.autrev.2017.10.005.
PMID: 29037902 - 12
Atypical Cogan's Syndrome with Large-vessel Vasculitis Successfully Treated with Tocilizumab.
Higashida-Konishi M, Akiyama M, Tabata H, et al.
Internal medicine (Tokyo, Japan) 2023; (62(22)):3413-3417 doi:10.2169/internalmedicine.1561-23.
PMID: 37032081 - 13
Tocilizumab Successfully Treating Refractory Hearing Impairment in a Patient With Cogan Syndrome: A Case Report and Review of the Literature.
Chen Y, Hu J, Wu D, et al.
Ear, nose, & throat journal 2024; 1455613241237079 doi:10.1177/01455613241237079.
PMID: 38494750 - 14
Speech reception after cochlear implantation for Cogan's syndrome: Case series following CARE guidelines.
Boumghit Y, Boucher S, Godey B, et al.
European annals of otorhinolaryngology, head and neck diseases 2023; (140(5)):235-238 doi:10.1016/j.anorl.2023.06.005.
PMID: 37479606 - 15
Optimal management of Cogan's syndrome: a multidisciplinary approach.
D'Aguanno V, Ralli M, de Vincentiis M, Greco A
Journal of multidisciplinary healthcare 2018; (11()):1-11 doi:10.2147/JMDH.S150940.
PMID: 29317827 - 16
Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan's Syndrome.
Shamriz O, Tal Y, Gross M
Journal of immunology research 2018; (2018()):1498640 doi:10.1155/2018/1498640.
PMID: 29850616 - 17
An unusual case of post-cochlear implant performance degradation in a patient with suspected Cogan's syndrome.
Low WK, See JY, Ng WN, et al.
Cochlear implants international 2019; (20(2)):94-99 doi:10.1080/14670100.2018.1548077.
PMID: 30474510 - 18
COVID-19-Induced Bilateral Sensorineural Hearing Loss in Cogan's Syndrome: A Case of Successful Cochlear Implantation in a Pediatric Patient.
Batuk IT, Icoz O, Batuk MO, Sennaroglu L
The journal of international advanced otology 2026; (22(1)):1-5 doi:10.65717/iao.2025.251922.
PMID: 42345423 - 19
Histopathology of the Human Inner Ear in the Cogan Syndrome with Cochlear Implantation.
Kamakura T, Lee DJ, Herrmann BS, Nadol JB
Audiology & neuro-otology 2017; (22(2)):116-123 doi:10.1159/000477534.
PMID: 28848089
This page is for informational purposes only and does not constitute medical advice. Your ophthalmologist, ear specialist, and prescribing team should tailor Cogan syndrome treatment and monitoring to your situation.